Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Atopic Keratoconjunctivitis
NCT04296864Phase 2Recruiting
- Sponsor
- Andover Eye Associates
- Start
- Feb 2020
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dupilumab in atopic keratoconjunctivitis (AKC), sponsored by Andover Eye Associates. Started Feb 2020; status: recruiting.
02
Drugs
03
Conditions
atopic keratoconjunctivitis (AKC)
Beyond the preview
Go deeper on NCT04296864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296864.